Amicus Therapeutics Stock News

Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

Amicus (FOLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Amicus (FOLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Karuna Therapeutics' (KRTX) first-quarter 2022 earnings beat estimates. Due to lack of marketed products in its portfolio, KRTX did not record any revenues during the quarter.

Allogene's (ALLO) first-quarter earnings beat estimates. Upon removal of the FDA's clinical hold on its AlloCAR T candidates, ALLO continues to move forward with its pipeline.

Amicus Therapeutics (FOLD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement

PHILADELPHIA, May 04, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2022 Healthcare Conference

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Despite the bear market, Amicus Therapeutics is enjoying aggressive sales growth for its lead medicine, Galafold, for Fabry. By mid-year, you are most likely to see another approval, that is, AT-GAA f

PHILADELPHIA, April 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 9, 2022 at 8:30 a

Although AT-GAA failed a phase 3 trial, there are reasons it could be approved.

Amicus Therapeutics Inc. ( FOLD , Financial) is the poster child for the malaise affecting small biotechs, especially those working on gene and cell therapy. Owners of the stock are hoping the company

Amicus Therapeutics Inc (NASDAQ: FOLD ) has announced additional results from a Phase 1/2 clinical study of AT-GAA in adult patients with Pompe disease. Study participants treated with AT-GAA for up to 36 months showed persistent and durable effects on six-minute walk test (6MWT) distance and other measures of motor function and … Full story available on Benzinga.com

Amicus Therapeutics (FOLD) reported additional results from a global phase 1/2 study (ATB200-02) of AT-GAA in adult patients with Pompe disease.Pompe disease is an inherited…